Edison Investment Research

In a report published Friday, Edison Investment Research analyst Bridie Barrett Schmidt initiated coverage on Emulex (NYSE: ELX), but did not assign a rating or price target. In the report, Edison Investment Research noted, “Emulex's longer-term prospects should become clearer as visibility on its...

In a report published Monday, Edison Investment Research analyst Gavin Wood commented on recent developments related to Silver Wheaton Corp. (NYSE: SLW). In the report, Edison Investment Research noted, “Silver Wheaton reported record production in Q313, although a declining silver price weighed...

In a report published Thursday, Edison Investment Research analyst Dr. Mike Aitkenhead commented on recent developments related to CytRx Corporation (NASDAQ: CYTR). In the report, Edison Investment Research noted, “Following positive aldoxorubicin data in soft tissue sarcoma (STS) and glioblastoma...

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on recent developments related to Halozyme Therapeutics (NASDAQ: HALO). In the report, Edison Investment Research noted, “With a positive CHMP opinion received for Herceptin SC, Halozyme is moved a step closer...

In a report published Wednesday, Edison Investment Research analyst Dr. Mike Aitkenhead commented on recent developments related to Threshold Pharmaceuticals (NASDAQ: THLD). In the report, Edison Investment Research noted, “Threshold has amended the protocol of its ongoing TH-302 Phase III study...

In a report published Wednesday, Edison Investment Research analyst Dan Ridsdale initiated coverage on Solera Holdings (NYSE: SLH). In the report, Ridsdale noted, “Solera is the leading supplier of productivity solutions to the global automotive repair industry. Diverse customer exposure and a...

In a report published Wednesday, Edison Investment Research analyst Dan Ridsdale commented on Silicom Ltd. (NASDAQ: SILC). In the report, Ridsdale noted, “Silicom's adapters and converters are essential components within many network and data infrastructure appliances. End-market growth is being...

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on Vertex Pharmaceuticals (NASDAQ: VRTX). In the report, Zhang noted, “Vertex's remarkable c $7.2bn (62%) increase in market capitalisation last week, on the back of VX-661 Phase IIa top-line data in cystic...

In a report published Thursday, Edison Investment Research analyst Michael Aitkenhead slightly raised the price target on CytRx Corporation (NASDAQ: CYTR) from $4.00 to $4.50. In the report, Aitkenhead noted, “CytRx and the FDA have agreed, on schedule, an SPA for the aldoxorubicin pivotal Phase...

In a report published Wednesday, Edison Investment Research analyst Jason Zhang, Ph.D. commented on Sarepta Therapeutics' (NASDAQ: SRPT) recent reaction to the FDA's request for additional information on eteplirsen. In the report, Zhang wrote, "The FDA's request for additional information from the...

In a research report published this morning, Edison Investment Research is waiting with bated breath on Oncolytics Biotech's (NASDAQ: ONCY) pending Phase III trial of Reolysin. According to Edison Investment Research, "This study is due to render interim data in mid-2012, which could be the...

In a research report published today by Edison, Esterline Technologies' (NYSE: ESL) Q1 results showed a vigorous start to the year as the Sourai acquisition added $83m to the already $471m in sales. In the report, Edison commented, “Esterline's Q1 results were in line with what was flagged at its...

Edison Investment Research provided color on Endocyte (NASDAQ: ECYT) in a research investment summary published today. In the report, Edison Investment Research states, "Endocyte now trading below its cash value and offers a very strong investment case, even on the worst-case scenario that EC145...

Edison Investment Research provided color on Pharmacyclics (NASDAQ: PCYC) in a research investment note published today. In the report, Edison Investment Research states, "Pharmacyclic's current EV of $609m looks reasonable given the attractive terms of the deal and stage of its pipeline. However...

Edison writes about Afferro Mining (NYSE: AFF), “Afferro has released its third NI 43-101 compliant resource estimate at its 100%-owned Nkout iron ore project. The overall resource base was increased by 41% to 2.0bn tonnes, with the potential DSO tonnage rising 70% to 19mt. As the drilling...